01 August 2026, Israel: Mercantile Life Science Ventures IV (MLSV) and Big Idea Ventures (BIV), via its Generation Food Rural Partners fund (GFRP), today announced a joint investment in Maia Fertility. The biotechnology company is advancing reproductive health through its proprietary sustained-release enzyme platform, Ferizyme™.
This funding will expand clinical studies across commercial cattle operations, providing the scientific foundation for future human medical applications.
A Partnership Built for Impact
The partnership leverages MLSV’s life sciences expertise and BIV’s agricultural acceleration to:
Advance Clinical Validation: Complete efficacy studies on commercial farms in North America and Europe.
Optimize Technology: Refine sustained-release delivery for maximum success rates.
Scale Markets: Drive livestock industry adoption while preparing healthcare infrastructure.
Voices Behind the Investment
“Ferizyme™ represents a fundamental rethinking of fertility. With MLSV and BIV, we have the infrastructure to prove this technology at scale and carry that momentum into the market,” said Nir Arbel, CEO of Maia Fertility.
“At Big Idea Ventures, we invest to support founders solving foundational challenges in the agriculture, food, and materials sectors. The science behind Ferizyme™ is compelling, the cattle market opportunity is immediate, and the long-term pathway into human reproductive health is transformative. We’re excited to accelerate what Maia Fertility has built.”
Tom Mastrobuoni, Chief Investment Officer, Big Idea Ventures
“Reproductive efficiency is key to both healthcare and agriculture. Mercantile is proud to bring this technology to the farms and clinics that need it most,” stated I. Steven Edelson, CEO of Mercantile Companies Inc.
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
